万古霉素与利奈唑胺治疗革兰阳性球菌感染性肺炎的疗效比较

Comparison of effects of vancomycin and linezolid on Gram-positive cocci infectious pneumoniai

目的比较万古霉素与利奈唑胺治疗革兰阳性球菌感染性肺炎的疗效。方法选取2018年12月至2020年3月济源市人民医院收治的革兰阳性球菌感染性肺炎患者97例,按照随机、对照原则将其分为万古霉素组和利奈唑胺组,对两组患者的临床疗效、细菌学疗效及不良反应发生情况进行评估分析。结果利奈唑胺组总治疗有效率(66.67%,34/51)明显高于对照组(52.17%,24/46),差异有统计学意义(P<0.05)。利奈唑胺组细菌清除率(80.39%,41/51)明显高于万古霉素组(58.70%,27/46),差异有统计学意义(P<0.05)。两组患者药物相关不良反应发生率比较,差异未见统计学意义(P>0.05)。结论采用利奈唑胺与万古霉素对革兰阳性球菌感染性肺炎患者进行治疗均可取得良好的抑菌效果和安全性,其中利奈唑胺的治疗效果更为显著,有利于缓解患者临床症状,保障其生命安全。

Objective To compare the effects of vancomycin and linezolid on Gram-positive cocci infection.Methods Ninety-seven patients with Gram-positive cocci pneumonia admitted in the People’s Hospital of Jiyuan from December 2018 to March 2020 were selected and divided into vancomycin group and linezolid group according to random and controlled principles.The clinical efficacy,bacteriological efficacy and adverse reactions of patients were evaluated and analyzed.Results The total treatment effective rate of patients in the linezolid group(66.67%,34/51)was significantly higher than that of the control group(52.17%,24/46),the difference was significant(P<0.05).The bacterial clearance rate in the linezolid group(80.39%,41/51)was significantly higher than that in the vancomycin group(58.70%,27/46),the difference was significant(P<0.05).There was no significant difference in the incidence of drug-related adverse reactions between the two groups(P>0.05).Conclusions Both Linezolid and vancomycin can achieve good bacteriostatic effect and safety in the treatment of patients with Gram-positive cocci infectious pneumonia,but linezolid is more effective.It is helpful to relieve patients'clinical symptoms and ensure their safety.